Annual report
4583.TEDINET S100VI6N
Period2024-01-01 → 2024-12-31
Filed2025-03-28
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 76
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥781m | 2024-01-01 → 2024-12-31 | Standalone | Net sales |
| Revenue | ¥682m | 2023-01-01 → 2023-12-31 | Standalone | Net sales |
| Revenue | ¥631m | 2022-01-01 → 2022-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥713m | 2021-01-01 → 2021-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥481m | 2020-01-01 → 2020-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥1.0bn | 2024-01-01 → 2024-12-31 | Standalone | Operating income |
| Operating income | −¥1.2bn | 2023-01-01 → 2023-12-31 | Standalone | Operating income |
| Ordinary income | −¥1.0bn | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.2bn | 2023-01-01 → 2023-12-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.2bn | 2022-01-01 → 2022-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.3bn | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.3bn | 2020-01-01 → 2020-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥1.0bn | 2024-01-01 → 2024-12-31 | Standalone | Income before income taxes |
| Profit before tax | −¥1.2bn | 2023-01-01 → 2023-12-31 | Standalone | Income before income taxes |
| Net income | −¥1.0bn | 2024-01-01 → 2024-12-31 | Standalone | Profit loss |
| Net income | −¥1.2bn | 2023-01-01 → 2023-12-31 | Standalone | Profit loss |
| Net income | −¥1.2bn | 2022-01-01 → 2022-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥1.5bn | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥1.3bn | 2020-01-01 → 2020-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥2.5bn | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥1.8bn | at 2023-12-31 | Standalone | Assets |
| Total assets | ¥2.2bn | at 2022-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.3bn | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥3.5bn | at 2020-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥549m | at 2024-12-31 | Standalone | Liabilities |
| Total liabilities | ¥594m | at 2023-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.9bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.2bn | at 2023-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.8bn | at 2022-12-31d | Standalone | Net assets |
| Net assets / equity | ¥1.9bn | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥3.1bn | at 2020-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.1bn | at 2024-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.3bn | at 2023-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥2.1bn | at 2024-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2023-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.7bn | at 2022-12-31d | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.8bn | at 2021-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥2.7bn | at 2020-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥1.0bn | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.1bn | 2023-01-01 → 2023-12-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.2bn | 2022-01-01 → 2022-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.1bn | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.4bn | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥173,000 | 2023-01-01 → 2023-12-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥35m | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥4m | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥1.7bn | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥667m | 2023-01-01 → 2023-12-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.1bn | 2022-01-01 → 2022-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥271m | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.9bn | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-17.54 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-24.62 | 2023-01-01 → 2023-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-28.26 | 2022-01-01 → 2022-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-36.74 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-36.06 | 2020-01-01 → 2020-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥28.53 | at 2024-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥21.66 | at 2023-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥36.7 | at 2022-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥45.55 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥77.99 | at 2020-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 77.4% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.1% | at 2023-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.2% | at 2022-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.4% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.2% | at 2020-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 66,969,000 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 52,640,200 | at 2023-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 48,423,500 | at 2022-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 40,781,500 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 39,505,200 | at 2020-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 47 | at 2024-12-31 | Standalone | Number of employees |
| Employees | 51 | at 2023-12-31 | Standalone | Number of employees |
| Employees | 49 | at 2022-12-31d | Standalone | Number of employees |
| Employees | 49 | at 2021-12-31d | Standalone | Number of employees |
| Employees | 42 | at 2020-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 21
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment assets | at 2024-12-31 | ¥2.5bn |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-12-31 | −¥527m |
| Drug Discovery And Developmentreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥203m |
| Drug Discovery And Developmentreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥203m |
| Drug Discovery And Developmentreportable segment | segment profit | 2024-01-01 → 2024-12-31 | −¥814m |
| Drug Discovery Supportreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥578m |
| Drug Discovery Supportreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥578m |
| Drug Discovery Supportreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥310m |
| —segment total | employees | at 2024-12-31 | 38 pure |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-01-01 → 2024-12-31 | ¥781m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-01-01 → 2024-12-31 | ¥781m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-01-01 → 2024-12-31 | −¥504m |
| Reconciling Itemsreconciling | segment assets | at 2023-12-31 | ¥1.8bn |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-12-31 | −¥552m |
| Drug Discovery And Developmentreportable segment | segment profit | 2023-01-01 → 2023-12-31 | −¥1.1bn |
| Drug Discovery Supportreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥682m |
| Drug Discovery Supportreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥682m |
| Drug Discovery Supportreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥399m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-01-01 → 2023-12-31 | ¥682m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-01-01 → 2023-12-31 | ¥682m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-01-01 → 2023-12-31 | −¥653m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 835
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 67769000 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 66969000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 67769000 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 1 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 31 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 99 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 23 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 159 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 27651 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 27964 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 1087 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 31654 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 4765 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 18253 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 1746 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 612053 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 669558 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 13200 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Percentage of shareholdings financial institutions | CurrentYearInstant_OrdinaryShareMember | 0.0016 | |
| Percentage of shareholdings financial service providers | CurrentYearInstant_OrdinaryShareMember | 0.0473 | |
| Percentage of shareholdings other corporations | CurrentYearInstant_OrdinaryShareMember | 0.0071 | |
| Percentage of shareholdings foreigners other than individuals | CurrentYearInstant_OrdinaryShareMember | 0.0273 | |
| Percentage of shareholdings foreign individuals | CurrentYearInstant_OrdinaryShareMember | 0.0026 | |
| Percentage of shareholdings individuals and others | CurrentYearInstant_OrdinaryShareMember | 0.9141 | |
| Number of shares held | CurrentYearInstant_No1MajorShareholdersMember | 1389900 | |
| Shareholding ratio | CurrentYearInstant_No1MajorShareholdersMember | 0.0207 | |
| Number of shares held | CurrentYearInstant_No2MajorShareholdersMember | 1100000 | |
| Shareholding ratio | CurrentYearInstant_No2MajorShareholdersMember | 0.0164 | |
| Number of shares held | CurrentYearInstant_No3MajorShareholdersMember | 1006258 | |
| Shareholding ratio | CurrentYearInstant_No3MajorShareholdersMember | 0.0150 | |
| Number of shares held | CurrentYearInstant_No4MajorShareholdersMember | 962700 | |
| Shareholding ratio | CurrentYearInstant_No4MajorShareholdersMember | 0.0143 | |
| Number of shares held | CurrentYearInstant_No5MajorShareholdersMember | 953500 | |
| Shareholding ratio | CurrentYearInstant_No5MajorShareholdersMember | 0.0142 | |
| Number of shares held | CurrentYearInstant_No6MajorShareholdersMember | 754601 | |
| Shareholding ratio | CurrentYearInstant_No6MajorShareholdersMember | 0.0112 | |
| Number of shares held | CurrentYearInstant_No7MajorShareholdersMember | 553200 | |
| Shareholding ratio | CurrentYearInstant_No7MajorShareholdersMember | 0.0082 | |
| Number of shares held | CurrentYearInstant_No8MajorShareholdersMember | 483000 | |
| Shareholding ratio | CurrentYearInstant_No8MajorShareholdersMember | 0.0072 | |
| Number of shares held | CurrentYearInstant_No9MajorShareholdersMember | 480000 | |
| Shareholding ratio | CurrentYearInstant_No9MajorShareholdersMember | 0.0071 | |
| Number of shares held | CurrentYearInstant_No10MajorShareholdersMember | 445600 | |
| Shareholding ratio | CurrentYearInstant_No10MajorShareholdersMember | 0.0066 | |
| Number of shares held | CurrentYearInstant | 8128759 | |
| Shareholding ratio | CurrentYearInstant | 0.1214 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 13 of 13 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |